Study identifier:D4880C00003
ClinicalTrials.gov identifier:NCT01843374
EudraCT identifier:2012-003524-21
CTIS identifier:2024-511841-20-00
A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma
Unresectable Pleural or Peritoneal Malignant Mesothelioma
Phase 2
No
Tremelimumab, Placebo
All
571
Interventional
18 Years - 99 Years
Allocation: Randomized
Endpoint Classification: Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Aug 2024 by MedImmune, LLC
MedImmune, LLC
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Tremelimumab Tremelimumab | Drug: Tremelimumab Tremelimumab is to be administered as an IV solution, followed by observation. |
Placebo Comparator: Placebo Placebo | Drug: Placebo Placebo is to be administered as an IV solution, followed by observation. |